Authors
GaoFeng Wang, Yuan Li
Published in
Discover oncology. Volume 16. Issue 1. Pages 874. May 23, 2025. Epub May 23, 2025.
Abstract
The aim of this study was to investigate the alteration of drug-resistant proteins in nasopharyngeal carcinoma (NPC) after intensity-modulated radiation therapy (IMRT) with or without chemotherapy and its correlation with clinicopathologic features and short-term prognosis.
Eligible NPC patients receiving IMRT with or without chemotherapy were studied. Tumor tissues from patients before treatment and at 2/3 of IMRT were obtained, and drug resistance proteins, P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), lung resistance protein (LRP), and glutathione S-transferase π (GST-π) were detected. Meanwhile, the clinicopathological data of the patients were collected and statistically analyzed. The short-term prognosis of the patients was observed and recorded, and the correlation between progression-free survival (PFS) and positive drug-resistant proteins was analyzed.
Before treatment, the positive rates of P-gp, MRP, LRP, and GST-π among the 43 NPC patients were 30.23%, 16.28%, 20.93%, and 34.88%, respectively; after treatment, the positive rates of P-gp and MRP were 65.12% and 41.86%, respectively (P-gp, P < 0.001; MRP, P = 0.009). Significantly higher positive rates of P-gp were observed only after treatment than before treatment in the IMRT-alone group (n = 18) and IMRT/chemotherapy group (n = 25). The intensity of P-gp, MRP and GST-π positive expression was increased in patients treated with IMRT/chemotherapy compared to pre-treatment. No correlation between positive expression of drug-resistant proteins and lymphatic metastasis was observed. Patients with P-gp and GST-π positivity had a more pronounced decrease in PFS.
P-gp, MRP, and GST-π are increased in NPC patients after IMRT with or without chemotherapy and are closely associated with poor short-term prognosis of patients.
PMID:
40407950
Bibliographic data and abstract were imported from PubMed on 23 May 2025.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 21
- Comments 0